X

Trial Profile

An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Apr 2018

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Octreotide
Indications Pancreatic cancer
Focus Pharmacogenomic; Registrational; Therapeutic Use
Acronyms RADIANT-1
Sponsors Novartis

Most Recent Events

12 Oct 2010 Results from this study and the other two RADIANT trials will form the basis for regulatory filings in late 2010 according to a Novartis media release.
24 Jun 2009 Final results presented at the 11th World Congress on Gastrointestinal Cancer.
17 Sep 2008 Added Novartis media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com